John M. Burke, MD

Articles

Dr. Burke on Risk Stratification Strategies in Follicular Lymphoma

September 28th 2020

John M. Burke, MD, discusses risk stratifications strategies in follicular lymphoma. 

Dr. Burke on Treatment Options in Relapsed/Refractory Follicular Lymphoma

September 25th 2020

John M. Burke, MD, discusses treatment options in relapsed/refractory follicular lymphoma.

Dr. Burke on the Potential of Time-Limited BTK Inhibitor Therapy in B-Cell Malignancies

September 23rd 2020

John M. Burke, MD, discusses the potential benefits of time-limited therapy with BTK inhibitors in B-cell malignancies.

Dr. Burke on Treatment Options in Low-Tumor Burden Follicular Lymphoma

September 16th 2020

John M. Burke, MD, discusses treatment options for patients with early-stage or advanced follicular lymphoma with a low tumor burden.

Dr. Burke on Tazemetostat’s Mechanism of Action in EZH2-Mutated Follicular Lymphoma

August 22nd 2020

John M. Burke, MD, discusses the role of tazemetostat in EZH2-mutated follicular lymphoma.

Dr. Burke on Current FDA Indications for BTK Inhibitors in B-Cell Malignancies

July 20th 2020

John M. Burke, MD, discusses current indications for BTK inhibitors in B-cell malignancies.

Dr. Burke on Research With Tafasitamab in Lymphoma

May 9th 2020

John M. Burke, MD, discusses research with tafasitamab (MOR208) in lymphoma.

Dr. Burke on the Ongoing First-MIND Trial With Tafasitamab in DLBCL

March 27th 2020

John M. Burke, MD, associate chair of the Hematology Research Program for US Oncology and medical oncologist and hematologist at Rocky Mountain Cancer Centers, discusses the ongoing phase Ib First-MIND trial in diffuse large B-cell lymphoma (DLBCL).

Dr. Burke on Findings of GOYA Study for Diffuse Large B-Cell Lymphoma

February 24th 2017

John M. Burke, MD, Rocky Mountain Cancer Centers, discusses the significant findings of the phase III GOYA study investigating obinutuzumab (Gazyva) plus CHOP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL).

Dr. Burke on a Study Investigating Obinutuzumab in Large B-Cell Lymphoma

December 5th 2016

John M. Burke, MD, discusses the GOYA study, a phase III study investigating obinutuzumab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma. Burke discussed the study during the American Society of Hematology (ASH) Annual Meeting.

x